KESHA MIMMS: Open Payments
NPI 1609343391 · HONOLULU, HI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$700 in 24 payments from 8 companies in 2025. Trend: 2023 $500 · 2024 $384 · 2025 $700
Food & beverage: $700
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 6 | $214 |
| Neurocrine BioSciences, Inc. | 5 | $163 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $135 |
| ABBVIE INC. | 3 | $73 |
| Alkermes, Inc. | 2 | $48 |
| Janssen Pharmaceuticals, Inc | 1 | $24 |
| E.R. Squibb & Sons, L.L.C. | 1 | $22 |
| Axsome Therapeutics, Inc. | 1 | $21 |
Products named: INGREZZA, ABILIFY MAINTENA, CAPLYTA, VRAYLAR, REXULTI, ARISTADA, INVEGA SUSTENNA, COBENFY.
Industry payments across HI — which companies pay providers there.
